The company plans to use proceeds to repurchase common stock and for general corporate purposes, including the repayment of outstanding commercial paper borrowings and upcoming debt maturities

Common stock in Fibrocell Science Inc., of Exton, Pa., has been approved for listing on the NYSE Market, to commence trading on May 17, under the ticker symbol FCSC

Acadia Pharmaceuticals Inc., of San Diego, priced a $100 million public offering of 8 million shares of common stock at $12.50 apiece, a 3.5 percent discount to Tuesday's closing price...Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J, said it is offering to sell shares of its common stock in a public offering

Omeros Corp., of Seattle, said it closed the registered direct offering of 3.9 million shares of common stock priced at $4.14 per share, raising net proceeds of about $16.1 million

Under the terms of its financing deal, Dyax priced a total of 8.9 million shares of common stock and 41,418 shares of Series 1 convertible preferred stock...MediciNova Inc., of San Diego, entered a securities purchase agreement, selling about 1.2 million shares of common stock priced at $3.15 apiece

Aastrom Biosciences Inc., of Ann Arbor, Mich., reported in an 8-K filing with the SEC that it was notified by Nasdaq that the bid price for its common stock closed below the minimum $1 per share requirement for 30 consecutive business days

The split is intended to increase the per-share trading price of the common stock to satisfy the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market...Trading of the company's common stock on the Nasdaq Capital Market will continue, on a split-adjusted basis, with the opening of the markets on May 13, under new CUSIP number 69207P308

Discovery Laboratories Inc., of Warrington, Pa., said it priced a $14.25 million public offering of 9.5 million shares of common stock at $1.50, an 8.5 percent discount to Thursday's closing price

The Carlsbad, Calif.-based company priced an underwritten public offering of 9 million shares of its common stock at $19 per share, seeking to raise $171 million from the offering, which is expected to close on or about May 14...In its filing, Isis said it would have 111.7 million shares of common stock outstanding when the offering closes

Receptos Inc., of San Diego, priced its initial public offering (IPO) of 5.2 million shares of common stock at $14 per share, for a total raise of $72.8 million...Senesco Technologies Inc., of Bridgewater, N.J., said it entered a securities purchase agreement with certain institutional investors to raise $1.255 million in gross proceeds through the sale of about 41 .8 million shares of common stock priced at 3 cents apiece

The increase is primarily due to proceeds of approximately $352 million received from a public offering of 4.4 million shares of common stock, completed in January

Under the terms, Zalicus has the right to sell up to $25 million in shares of its common stock to Lincoln Park subject to certain limitations and conditions set forth in the purchase agreement...Zalicus will control the timing and amount of any common stock sales to Lincoln Park.

A spokesman for GeneMedicine told BioWorld Today Blech currently owns 1 million shares of that company's common stock, but has no active involvement in its operation

plans to purchase up to $15 billion of its common stock

to sell shares of common stock 4/19/13 Navidea Biopharma-ceuticals Inc. (Dublin, Ohio) At-the-market common stock offering 2.1S $5.1 Navidea raised $5.1M in an offering of 2.1M shares at $2.43 per share

7 iBio's units consisted of common stock and warrants to purchase 3.57M shares

1 million shares of common stock, with underwriters exercising their overallotment option in full, purchasing an additional 469,483 shares...Insys Therapeutics Inc., of Phoenix, priced its initial public offering of 4 million shares of common stock at $8 apiece, coming in at the low end of its $8 to $10 range, for gross proceeds of $32 million

The private placement of common stock and warrants to purchase common stock represents a final closing, which generated a total of $39.3 million, including $6.8 million from prior closings, The financing, the company expects, will fully fund the Phase III randomized, controlled study comparing CPX-351 for first-line therapy to conventional cytarabine and daunorubicin therapy (7 + 3) in patients, 60-75, with secondary acute myeloid leukemia (AML), with a primary endpoint of overall survival

Inc., of Whitehouse Station, N.J., said its board authorized additional purchases of up to $15 billion of Merck's common stock for its treasury...The company expects to repurchase about $7.5 billion of common stock over the next 12 months, financed through a combination of debt issuance and operating cash flows, with the remainder to be repurchased over time with no time limit